BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
How expensive is the stock market right now? BioNTech (NASDAQ: BNTX) vaulted into the spotlight in 2020 when Pfizer teamed up ...
Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
Berenberg Bank Remains a Buy on BioNTech SE (BNTX)
Berenberg Bank analyst Harry Gillis maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of ...
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the ...